AUS
NZ
UK
CA
USA
IND
As of 2024, ASX growth stock Resmed CDI has experienced a remarkable 23.4% rise in its share price, reflecting its strong performance and growing presence in the medical equipment sector. In contrast, Coles Group Ltd remains relatively stable, trading 4% above its 52-week lows. This article provides an overview of both companies, highlighting Resmed’s advancements in sleep and respiratory care technology, and Coles’ extensive retail operations and market diversification. We also explore the valuation insights for Resmed to understand its current share price dynamics.
Resmed CDI (ASX:RMD)
Resmed CDI has shown a significant increase in its share price, rising by 23.4% since the start of 2024. Resmed, initially founded in 1989 in Australia, has grown to become a leading global player in the medical equipment industry. Although it originated in Australia, the company is now headquartered in San Diego, California. Resmed specializes in providing advanced medical equipment for the treatment of obstructive sleep apnea (OSA), particularly through its cloud-connectable continuous positive airway pressure (CPAP) machines. These devices are recognized as the most effective therapy for all severities of OSA.
Operating on a global scale, Resmed employs over 10,000 people and maintains a presence in more than 140 countries. The company’s operations are divided into two main business units: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care unit focuses on providing high-quality CPAP machines and other related devices. This unit serves a wide range of patients, from those needing CPAP therapy at night to individuals requiring more intensive non-invasive or invasive ventilation.
In addition to its hardware offerings, Resmed’s SaaS division plays a crucial role in supporting durable or home medical equipment (DME/HME) management. This division leverages Resmed’s large digital health network, powered by cloud-connected devices, to deliver valuable insights and improve healthcare outcomes. The integration of hardware and SaaS data not only enhances patient care but also helps in reducing overall healthcare costs.
Coles Group’s (ASX:COL)
Coles Group Ltd, a prominent Australian retailer, is currently trading 4% above its 52-week lows. Founded in 1914 and headquartered in Victoria, Coles has established itself as a leading provider of a wide range of products. The company’s offerings include fresh food, groceries, general merchandise, liquor, fuel, and financial services. Coles was previously part of the conglomerate Wesfarmers, which owned it from 2007 until 2018. In 2018, Coles was spun off and listed as an independent entity on the ASX under the ticker symbol ‘COL’.
While Coles’ earnings are predominantly driven by its supermarket operations, the company also has a diverse portfolio of associated businesses. These include flybuys, Liquorland, First Choice, Vintage Cellars, and Coles Express. This diversification helps Coles maintain a strong market presence and provide a comprehensive range of services to its customers.
Valuation Insights
When evaluating Resmed’s share price, one useful metric is the price-to-sales ratio. Currently, Resmed’s price-to-sales ratio stands at 4.84x. This figure is below its 5-year average of 7.81x, suggesting that the company’s shares are trading at a lower valuation compared to their historical norms. This ratio provides a rough estimate of the company’s share value in relation to its sales revenue. However, it is important to consider this metric in conjunction with other factors when assessing the investment potential of Resmed’s shares.
Both Resmed and Coles Group offer unique investment opportunities within their respective sectors. Resmed’s significant growth in the medical equipment industry and its innovative use of cloud-connected technology highlight its strong market position. Meanwhile, Coles Group’s extensive retail operations and diversified business model contribute to its resilience and market stability.
